In B-ALL, NFE2L2 overexpression hinders tumour sensitivity to vincristine, and this occurs through the PI3K-AKT-mTOR pathway [27]. This evidence concerns the gene NFE2L2 and precursor B-cell acute lymphoblastic leukemia.